UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 28, 2021

Arvinas, Inc.
(Exact name of registrant as specified in its charter)

Delaware	**001-38672**	**47-2566120**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

5 Science Park **395 Winchester Ave.** **New Haven, Connecticut**	**06511**
(Address of principal executive offices)	**(Zip Code)**

Registrant's telephone number, including area code: (203) 535-1456

Not applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.001 per share	**ARVN**	**The Nasdaq Stock Market LLC**

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On September 28, 2021, Arvinas, Inc. (the "Company") posted an updated corporate presentation on the "Investors + Media" section of the Company's website (www.arvinas.com). The information contained in, or that can be accessed through, the Company's website is not a part of this filing. The updated portion of the presentation regarding the timing of clinical data for the Company's ARV-110 clinical program is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 8.01 Other Events.

On September 28, 2021, the Company announced updated timing for the anticipated presentation of clinical data for the Company's ARV-110 clinical program. The Company anticipates presenting data from the dose escalation portion and interim data from the ARDENT expansion portion of its Phase 1/2 clinical trial of ARV-110 at the ASCO Genitourinary Cancers Symposium in February 2022.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Excerpt from Company Presentation, dated September 28, 2021
104	Cover Page Interactive Data File (formatted as Inline XBRL)

Forward-Looking Statements

This Current Report on Form 8-K, including the document furnished as Exhibit 99.1 hereto, contains forward-looking statements that involve substantial risks and uncertainties, including statements regarding the development and regulatory status of the Company's product candidates, such as statements with respect to the Company's lead product candidates, ARV-110, ARV-471 and ARV-766 and other candidates in the Company's pipeline, and the timing of clinical trials and data from those trials and plans for registration for the Company's product candidates, and the Company's development programs that may lead to the Company's development of additional product candidates, the potential utility of the Company's technology and therapeutic potential of the Company's product candidates and the potential commercialization of any of the Company's product candidates. All statements, other than statements of historical facts, contained in this Current Report on Form 8-K, including statements regarding the Company's strategy, future operations, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements the Company makes as a result of various risks and uncertainties, including but not limited to: whether the Company will be able to successfully conduct Phase 1/2 clinical trials for ARV-110, ARV-471 and ARV-766, complete its clinical trials for its product candidates, and receive results from its clinical trials on the Company's expected timelines, or at all, whether the Company's cash resources will be sufficient to fund its foreseeable and

unforeseeable operating expenses and capital expenditure requirements, the Company's expected timeline and other important factors discussed in the "Risk Factors" sections contained in the Company's quarterly and annual reports on file with the Securities and Exchange Commission. The forward-looking statements contained in this Current Report on Form 8-K reflect the Company's current views with respect to future events, and the Company assumes no obligation to update any forward-looking statements except as required by applicable law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this Current Report on Form 8-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 28, 2021

ARVINAS, INC.

By: /s/ Sean Cassidy
Sean Cassidy
Chief Financial Officer

Rapid pace of anticipated milestones

Exhibit 99.1

	2021	2022
ARV-471 (ER PROTAC®)	• Share completed Phase 1 data (*anticipated at SABCS*) • Initiate Phase 1b combination study with everolimus • Begin early breast cancer study (neoadjuvant setting)	• Initiate Phase 3 studies in metastatic breast cancer (as monotherapy and in combination) • VERITAC Phase 2 data • Safety data from Phase 1b IBRANCE® (palbociclib) combination study data
ARV-110 (AR PROTAC®)	• Initiate abiraterone combination study	• Share complete Phase 1 dose escalation and interim ARDENT Phase 2 data (*anticipated at ASCO GU*) • Share completed ARDENT Phase 2 data • Share interim abiraterone combination data
ARV-766 (AR PROTAC®)	• Initiate Phase 1	• Share Phase 1 data • Initiate Phase 2
INDs	• Four additional INDs through 2023	

ARVINAS